Brief: Sedana Medical U.S. Studies Meet First Key Secondary Endpoint
10/06/2025 07:08
June 10 (Reuters) - Sedana Medical AB (publ) SEDANA.ST: US STUDIES MEET FIRST KEY SECONDARY ENDPOINT SIGNIFICANT OPIOID DOSE REDUCTION FOUND IN ISOFLURANE GROUP NO NEW SAFETY SIGNALS FOR ISOFLURANE IN SEDANA MEDICAL STUDIES Source text: ID:nMFN6qNyg3 Further company coverage: SEDANA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln